A. Prasse (Freiburg, Germany), T. Maher (London, United Kingdom), M. Vasakova (Prague 4, Czech Republic), P. Spagnolo (Modena, Italy)
Prognostic value of dual-time-point 18F-FDG PET in fibrotic idiopathic interstitial pneumonia
Y. Umeda, Y. Demura, C. Honjo, Y. Sumida, M. Morikwa, M. Anzai, S. Ameshima, T. Tsuchida, H. Okazawa, T. Ishizaki, T. Ishizuka (Fukui, Kanazawa, Japan)
|  |
Mesenchymal stem cells from adipose tissue reduce bleomycin-induced lung remodeling in late stage
R. G. Felix, A. T. Fabro, J. C. V. Oliveira, M. J. A. Valerio, O. S. Cotrim, C. Cunha, C. R. G. Lima, E. H. Bianchi, M. A. C. Domingues, J. T. R. Paes, E. Deffune (Botucatu, Assis, Brazil)
| |
Difference in the dynamic state between SP-A and SP-D in the IPF lung
H. Nishikiori, H. Chiba, M. Otsuka, K. Ikeda, H. Takahashi (Sapporo, Japan)
| |
The immunomodulatory effect of protein S in pulmonary fibrosis
T. Takagi, M. Urawa, A. Tomaru, K. Fujiwara, M. Onishi, T. Kobayashi, H. Kobayashi, M. Toda, C. D'Alessandro-Gabazza, E. Gabazza, O. Taguchi (Tsu, Japan)
|  |
What is significant sleep disordered breathing in patients with interstitial lung disease?
L. Troy, K. Wong, B. Yee, N. Taylor, R. Grunstein, P. Corte, P. Torzillo, T. Corte (Camperdown, Sydney, Sydney, Australia)
| |
Clinical significance of hemosiderin-laden macrophages in bronchoalveolar lavage fluid of patients with idiopathic interstitial pneumonias
T. Kagawa, T. Arai, C. Sugimoto, K. Tachibana, T. Tsuji, Y. Matsuda, Y. Sasaki, R. Sugawara, Y. Inoue, Y. Fujita, T. Teramoto, M. Kitaichi, S. Hayashi, Y. Inoue (Sakai, Japan)
| |
Incidence of idiopathic pulmonary fibrosis in Italy. Analysis of hospital admission and mortality databases of a large Italian region
M. A. Porretta, L. Bauleo, A. Coppola, G. Sergiacomi, M. C. Zappa, S. Carlone, S. Mariotta, P. Palange, S. Valente, G. Pezzuto, N. Agabiti, M. Pallante, E. Puxeddu, C. Saltini (Roma, Rome, Italy)
| |
A longitudinal study of anxiety and depression in idiopathic pulmonary fibrosis (IPF)
K. Pink, J. Boylan, B. Hope-Gill (Cardiff, United Kingdom)
| |
Lung cancer in patients with idiopathic pulmonary fibrosis: Clinical characteristics and impact on survival
J. S. Park, T. Lee, J. Y. Park, H. Y. Lee, H. J. Lim, Y. J. Cho, H. I. Yoon, J. H. Lee, S. Jheon, C. G. Yoo, C. T. Lee, S. K. Han (Seongnam, Seoul, Republic Of Korea)
| |
A proof of concept study by thrombomodulin for acute exacerbations of idiopathic pulmonary fibrosis
K. Tsushima, T. Yokoyama, Y. Ichimura, K. Tatsumi (Chiba, Matsumoto, Japan)
| |
Tranilast inhibits pulmonary fibrosis by suppressing TGFbeta-mediated extracellular matrix protein production
M. Kato, F. Takahashi, T. Sato, F. Nurwidya, I. Kobayashi, Y. Hoshika, A. Murakami, R. Ko, S. Yagishita, M. Yoshioka, N. Shimada, Y. Yoshioka, M. Takahashi, H. Saya, K. Takahashi (Tokyo, Japan)
| |
Idiopathic pulmonary fibrosis (IPF) and gastroeosophageal disorders
J. Kokeza, K. Mise, Z. Puljiz, A. Bradaric, E. Lozo, J. Mise (Split, Zagreb, Croatia)
| |
MUC5B promoter polymorphism is significantly associated with idiopathic interstitial pneumonia in German but not in Japanese patients
Y. Horimasu, N. Hattori, N. Ishikawa, S. Tanaka, F. Bonella, S. Ohshimo, J. Guzman, U. Costabel, N. Kohno (Hiroshima, Japan; Essen, Bochum, Germany)
| |
Real World experiences: Pirfenidone is well tolerated and reduces decline in FVC and TLCO at 9 months in IPF
N. Chaudhuri, A. Duck, J. Holme, R. Frank, C. Leonard (Manchester, United Kingdom)
| |
Effect of pirfenidone (PFD) on cytokine/chemokine release from alveolar macrophages (AMs) in interstitial lung diseases (ILD): Preliminary results
X. He, D. Theegarten, J. Guzman, U. Costabel, F. Bonella (Essen, Bochum, Germany)
| |
Pirfenidone in idiopathic pulmonary fibrosis - Real life experience from a german tertiary referral centre for interstitial lung diseases
U. Oltmanns, N. Kahn, H. Wenz, C. P. Heussel, M. Puderbach, S. Ehlers-Tenenbaum, A. Warth, F. Herth, P. Schnabel, M. Kreuter (Heidelberg, Germany)
| |
Diffusing capacity for carbon monoxide (DLco) may predict appearance of pulmonary hypertension in idiopathic pulmonary fibrosis
M. Otsuka, Y. Kitamura, K. Yokoo, K. Ikeda, M. Shioya, H. Nishikiori, M. Shiratori, H. Takahashi (Sapporo, Japan)
| |
Aquoaporin-1 expression in idiopathic pulmonary fibrosis
C. Gutiérrez, A. Donate, L. Gómez Izquierdo, M. Molina-Molina, M. Echevarría, J. A. Rodriguez Portal (Sevilla, Bellvitge, Spain)
| |
Possible indication for surgical resection of lung cancer associated with combined pulmonary fibrosis and emphysema (CPFE)
Y. Mizokami, A. Masunaga, S. Yoshitake, K. Kojima, H. Sakata, S. Hirosako, S. Okamoto, H. Ichiyasu, K. Fujii, N. Saita, K. Yoshimoto, T. Mori, M. Suzuki, H. Kohrogi (Kumamoto, Japan)
| |
Clinical significance of autoantibody screening in patients with idiopathic pulmonary fibrosis
M. E. M. Wilkie, J. D. Chalmers, R. P. Smith, S. Schembri (Dundee, United Kingdom)
| |